Patents by Inventor Patrick Florent

Patrick Florent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
    Patent number: 8623380
    Abstract: The invention provides a diphtheria, tetanus and pertussis vaccine comprising a low dose of each of diphtheria toxoid (D), tetanus toxoid (T), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (69K). The vaccine maintains an ability to prevent pertussis while showing exceptionally low reactogenicity. Combination vaccines comprising additional antigens are also provided.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: January 7, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Patrick Florent, Jean Stephenne, Christian Vandecasserie
  • Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
    Publication number: 20040208898
    Abstract: The invention provides a diphtheria, tetanus and pertussis vaccine comprising a low dose of each of diphtheria toxoid (D), tetanus toxoid (T), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (69K). The vaccine maintains an ability to prevent pertussis while showing exceptionally low reactogenicity. Combination vaccines comprising additional antigens are also provided.
    Type: Application
    Filed: May 4, 2004
    Publication date: October 21, 2004
    Applicant: SmithKline Beecham Biologicals S.A.
    Inventors: Patrick Florent, Jean Stephenne, Christian Vandecasserie
  • Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
    Publication number: 20010014331
    Abstract: This invention relates to a diphtheria, tetanus and pertussis vaccine comprising a low dose of each of diphtheria toxoid (D), tetanus toxoid (T), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (69K). The vaccine maintains an ability to prevent pertussis while showing exceptionally low reactogenicity. Combination vaccines comprising additional antigens are also provided.
    Type: Application
    Filed: April 6, 2001
    Publication date: August 16, 2001
    Applicant: SmithKline Beecham Biologicals s.a.
    Inventors: Patrick Florent, Jean Stephenne, Christian Vandecasserie